Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CPB1 | P15086 | 4/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19628551 | 0.85 | CPB2 (0.46) | CPB2CYP2C9CYP2C19TSHRMTOR | |
| SCHEMBL589342 | 0.83 | CYP2C9 (0.60) | CPB2CYP2C9CYP2C19CYP2E1CYP3A4 | |
| SCHEMBL1303332 | 0.83 | CPB2 (0.39) | CPB2CYP2C9CYP2C19CYP2E1CYP3A4 | |
| SCHEMBL5239518 | 0.83 | CPB2 (0.39) | CPB2CYP2C9CYP2C19CYP2E1CYP3A4 | |
| SCHEMBL3955613 | 0.82 | — | — | |
| SCHEMBL12363417 | 0.80 | TSHR (0.43) | CPB2CYP2C9CYP2C19CYP3A4TSHR | |
| SCHEMBL12015010 | 0.80 | CPB2 (0.40) | CPB2CYP2C9CYP2C19CYP2E1CYP3A4 | |
| SCHEMBL1908661 | 0.80 | CPB2 (0.43) | CPB2CYP2C9CYP2C19CYP2E1CYP3A4 | |
| SCHEMBL6377614 | 0.80 | CPB2 (0.43) | CPB2CYP2C9CYP2C19CYP2E1CYP3A4 | |
| SCHEMBL6181814 | 0.79 | CPB2 (0.40) | CPB2CYP2C9CYP2C19CYP2E1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637557-B2 | Aminothiazole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20120220767-A1 | AMINOTHIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| EP-2357179-A1 | Thiazol-2-yl organic compounds | Novartis AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| WO-2011048936-A1 | AMINOTHIAZOLE DERIVATIVE | 大正製薬株式会社 (JP) | 2011-04-28 | — | — | WO | disclosed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | disclosed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| WO-2007068473-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220767-A1 | AMINOTHIAZOLE DERIVATIVE | AKT3, AKT2, JAK1 | CPB2 4266/4885CYP2C9 2083/4885CYP2C19 2446/4885 |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | AKT3, PIK3R3, PIK3CD | CPB2 2672/4885CYP2C9 3872/4885CYP2C19 2458/4885 |
| US-20100197682-A1 | Organic Compounds | PIK3CA, PI4KA, PI4KB | CPB2 3413/4885CYP2C9 4027/4885CYP2C19 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.